Crizotinib nearly doubles progression-free survival in patients with ALK-positive lung cancer

被引：0
|
作者：
Mayor, Susan
机构：
来源：
BRITISH JOURNAL OF HOSPITAL MEDICINE | 2012年 / 73卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：610 / 610
页数：1
相关论文
共 50 条
  • [1] Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib
    Gainor, Justin F.
    Tan, Daniel S. W.
    De Pas, Tomasso
    Solomon, Benjamin J.
    Ahmad, Aziah
    Lazzari, Chiara
    de Marinis, Filippo
    Spitaleri, Gianluca
    Schultz, Katherine
    Friboulet, Luc
    Yeap, Beow Y.
    Engelman, Jeffrey A.
    Shaw, Alice T.
    CLINICAL CANCER RESEARCH, 2015, 21 (12) : 2745 - 2752
  • [2] Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer
    Ock, Chan-Young
    Yoo, Shin-Hye
    Keam, Bhumsuk
    Kim, Miso
    Kim, Tae Min
    Jeon, Yoon Kyung
    Kim, Dong-Wan
    Chung, Doo Hyun
    Heo, Dae Seog
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2019, 34 (05): : 1116 - +
  • [3] Crizotinib in ALK-positive lung cancer
    Girard, Nicolas
    LANCET ONCOLOGY, 2012, 13 (10): : 962 - 963
  • [4] Short progression-free survival of ALK inhibitors sensitive to secondary mutations in ALK-positive NSCLC patients
    Haratake, Naoki
    Seto, Takashi
    Takamori, Shinkichi
    Toyozawa, Ryo
    Nosaki, Kaname
    Miura, Naoko
    Ohba, Taro
    Toyokawa, Gouji
    Taguchi, Kenichi
    Yamaguchi, Masafumi
    Shimokawa, Mototsugu
    Takenoyama, Mitsuhiro
    THORACIC CANCER, 2019, 10 (09) : 1779 - 1787
  • [5] Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC).
    Camidge, D. R.
    Bang, Y.
    Kwak, E. L.
    Shaw, A. T.
    Iafrate, A. J.
    Maki, R. G.
    Solomon, B. J.
    Ou, S. I.
    Salgia, R.
    Wilner, K. D.
    Costa, D. B.
    Shapiro, G.
    LoRusso, P.
    Stephenson, P.
    Tang, Y.
    Ruffner, K.
    Clark, J. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] The efficacy of crizotinib in patients with ALK-positive nonsmall cell lung cancer
    Pender, Alexandra
    Popat, Sanjay
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2015, 9 (03) : 97 - 104
  • [7] Expanding opportunities for crizotinib resistance in ALK-positive lung cancer patients
    Ilie, Marius
    Hofman, Paul
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 (02) : 203 - 205
  • [8] Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer
    Nakagawa, Kazuhiko
    Hida, Toyoaki
    Nokihara, Hiroshi
    Morise, Masahiro
    Azuma, Koichi
    Kim, Young Hak
    Seto, Takashi
    Takiguchi, Yuichi
    Nishio, Makoto
    Yoshioka, Hiroshige
    Kumagai, Toru
    Hotta, Katsuyuki
    Watanabe, Satoshi
    Goto, Koichi
    Satouchi, Miyako
    Kozuki, Toshiyuki
    Koyama, Ryo
    Mitsudomi, Tetsuya
    Yamamoto, Nobuyuki
    Asakawa, Takashi
    Hayashi, Morihiko
    Hasegawa, Wakako
    Tamura, Tomohide
    LUNG CANCER, 2020, 139 : 195 - 199
  • [9] Is there a progression-free survival benefit of first-line crizotinib versus standard chemotherapy and second-line crizotinib in ALK-positive advanced lung adenocarcinoma? A retrospective study of Chinese patients
    Cui, Shaohua
    Zhao, Yizhuo
    Dong, Lili
    Gu, Aiqin
    Xiong, Liwen
    Qian, Jialin
    Zhang, Wei
    Niu, Yanjie
    Pan, Feng
    Jiang, Liyan
    CANCER MEDICINE, 2016, 5 (06): : 1013 - 1021
  • [10] Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
    Shaw, Alice T.
    Kim, Dong-Wan
    Nakagawa, Kazuhiko
    Seto, Takashi
    Crino, Lucio
    Ahn, Myung-Ju
    De Pas, Tommaso
    Besse, Benjamin
    Solomon, Benjamin J.
    Blackhall, Fiona
    Wu, Yi-Long
    Thomas, Michael
    O'Byrne, Kenneth J.
    Moro-Sibilot, Denis
    Camidge, D. Ross
    Mok, Tony
    Hirsh, Vera
    Riely, Gregory J.
    Iyer, Shrividya
    Tassell, Vanessa
    Polli, Anna
    Wilner, Keith D.
    Jaenne, Pasi A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (25): : 2385 - 2394
12345